523 related articles for article (PubMed ID: 19664015)
1. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
2. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
Johnston A
Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
Gruppo RA; Brown D; Wilkes MM; Navickis RJ
Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.
Gringeri A; Tagliaferri A; Tagariello G; Morfini M; Santagostino E; Mannucci P;
Br J Haematol; 2004 Aug; 126(3):398-404. PubMed ID: 15257713
[TBL] [Abstract][Full Text] [Related]
6. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
7. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
[TBL] [Abstract][Full Text] [Related]
8. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.
Khrenov AV; Ananyeva NM; Saenko EL
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):379-88. PubMed ID: 16788314
[TBL] [Abstract][Full Text] [Related]
9. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
[TBL] [Abstract][Full Text] [Related]
10. Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII.
Gruppo RA; Brown D; Wilkes MM; Navickis RJ
Haemophilia; 2004 Nov; 10(6):747-50. PubMed ID: 15569174
[TBL] [Abstract][Full Text] [Related]
11. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
Singleton E; Smith J; Kavanagh M; Nolan B; White B
Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
Klukowska A; Windyga J; Batorova A
Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
[TBL] [Abstract][Full Text] [Related]
13. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
Berntorp E; Figueiredo S; Futema L; Pock K; Knaub S; Walter O; Trawnicek L; Römisch J
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):577-83. PubMed ID: 20644466
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
[TBL] [Abstract][Full Text] [Related]
16. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
Klintman J; Hillarp A; Donfield S; Berntorp E; Astermark J
Haemophilia; 2013 Jan; 19(1):106-12. PubMed ID: 22762454
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
19. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
